riociguat

(redirected from Adempas)

riociguat

(rye-oh-sig-ue-at ) ,

Adempas

(trade name)

Classification

Therapeutic: pulmonary hypertension agents
Pharmacologic: soluble guanylate cyclase stimulators sgs
Pregnancy Category: X

Indications

Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH, WHO Group 4) after surgery or in non-surgical candidates.Treatment of pulmonary arterial hypertension (PAH, WHO Group 1)

Action

Stimulates soluble guanyl cyclase (sGC) a cardiopulmonary enzyme and receptor for nitric oxide, which when stimulated produces cyclic guanine monophosphate, an important regulator of vascular tone, proliferation, fibrosis and inflammation. This pathway is dysregulated in pulmonary hypertension.

Therapeutic effects

Improved symptoms/exercise tolerance and delayed worsening.

Pharmacokinetics

Absorption: Well absorbed following oral administration (94%)
Distribution: Unknown.
Protein Binding: 95%
Metabolism and Excretion: Extensively metabolized (by CYP P1A1, CYP3A, CYP2C8, and CYP2J2); M1 metabolite is pharmacologically active; metabolites are excreted in urine and feces (great individual variation)
Half-life: 12 hr

Time/action profile (improvement in 6–min walk distance)

ROUTEONSETPEAKDURATION
POwithin 2 wk8–16 wkunknown

Contraindications/Precautions

Contraindicated in: Severe hepatic impairment (Child Pugh C)Severe renal impairment (CCr <15 mL/min or on dialysis)Known pulmonary veno-occlusive disease; Concurrent use of nitrates, nitric oxide donors or phosphodiesterase (PDE) inhibitors; Obstetric: May cause fetal harm, pregnancy should be avoided (negative pregnancy tests required before and monthly during treatment) Lactation: Discontinue breast feeding
Use Cautiously in: Resting hypotension, hypovolemia, severe left-ventricular outflow obstruction, autonomic dysfunction, concurrent antihypertensive therapy or CYP and p-gp/BCRP inhibitors (↑ risk of hypotension, consider dose reduction); Cigarette smokers (require ↑ doses, with subsequent adjustment if smoking is stopped)Patients with reproductive potential (effective contraception is required) Geriatric: Elderly may have ↑ blood levels and be more sensitive to drug effects; Pediatric: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness (most frequent)
  • headache (most frequent)

Cardiovascular

  • pulmonary edema (↑ in veno-occlusive disease)
  • hypotension (most frequent)

Gastrointestinal

  • dyspepsia (most frequent)
  • gastritis (most frequent)
  • nausea (most frequent)
  • vomiting (most frequent)
  • constipation
  • diarrhea
  • gastroesopheal reflux
  • ↑ liver enzymes

Hematologic

  • bleeding (life-threatening)
  • anemia

Interactions

Drug-Drug interaction

↑ risk of hypotension with concurrent use of nitrates, nitric oxide donors (including amyl nitrate ) or phosphodiesterase (PDE) inhibitors including specific PDE-5 inhibitors such as sildenafil, tadalafil or vardenafil and non-specific PDE inhibitors such as dipyridamole or theophylline, concurrent use is contraindicated Strong CYP and P-gp/BRCP inhibitors including azole antifungals (ketoconazole and itraconazole ) and protease inhibitors (ritonavir ) ↑ blood levels and the risk of adverse reactions including hypotension (consider ↓ initial dose).Strong CYP3A inducers including carbamazepine, phenobarbital, phenytoin and rifampin ↓ blood levels and may ↓ effectiveness.Concurrent use of antihypertensives including diuretics may ↑ risk of hypotension.Antacids ↓ absorption (separate doses by at least 1 hr)Cigarette smoking ↓ blood levels and effectiveness, ↑ dose may be necessary and dose re-adjustment required after smoking cessation.St. John's wort ↓ blood levels and may ↓ effectiveness.

Route/Dosage

Oral (Adults) 1 mg three times daily initially; if hypotension a risk factor, initiate treatment with 0.5 mg three times daily. Increase dose by 0.5 mg at 2 wk (or more) intervals up to maintenance dose of 2.5 mg three times daily; smokers— consider titrating to doses >2.5 mg three times daily if tolerated (re-adjust following smoking cessation); concurrent CYP and P-gp/BRCP inhibitors— consider initiating treatment at 0.5 mg three times daily, with careful monitoring for hypotension.

Availability

Tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg

Nursing implications

Nursing assessment

  • Monitor hemodynamic parameters and exercise tolerance prior to and every 2 wks during therapy.
  • Assess for signs and symptoms of pulmonary edema (shortness of breath). If confirmed, discontinue therapy.
  • Monitor patient for bleeding (hemoptysis, vagina, catheter site, hematemesis, intra-abdominal, cerebral) during therapy.
  • Lab Test Considerations: Obtain a negative pregnancy test prior to beginning, monthly during therapy, and 1 mo following treatment.
    • Monitor hepatic function periodically during therapy. May cause ↑ AST, ALT, and bilirubin. If clinically relevant ↑ of AST or ALT occur, or if ↑ are accompanied by ↑ bilirubin >2 x upper limit of normal, or by clinical symptoms of hepatotoxicity, discontinue therapy. May re­initiate therapy when hepatic enzyme levels normalize in patients who have not experienced clinical symptoms of hepatotoxicity.
    • Monitor CBC before starting and periodically during therapy. May cause anemia. Avoid therapy in patients with severe anemia.

Potential Nursing Diagnoses

Activity intolerance (Indications)

Implementation

  • Only available through a restricted program, Adempas Risk Evaluation and Mitigation Strategy (REMS). Prescribers and pharmacies must be enrolled and certified. All female patients must enroll and comply with pregnancy testing and contraception requirements. Male patients do not need to enroll.
  • Oral: Administer 3 times daily. If patient at risk for hypotension, begin with 0.5 mg dose. If systolic BP >95 and patient is asymptomatic, may increase by 0.5 mg three times/day up to 2.5 mg three times daily. Do not increase sooner than every 2 wks. If symptoms of hypotension occur, decrease dose by 0.5 mg three times/day. If dose is missed more than 3 days, begin titration again.
    • Titrate patients who smoke to doses >2.5 mg three times/day, if tolerated. May need to decrease dose if patient stops smoking.
    • May be administered without regard to food.

Patient/Family Teaching

  • Instruct patient to take riociguat as directed. If dose is missed, omit and continue with next scheduled dose.
  • Advise patient to avoid taking antacids within 1 hr of riociguat.
  • Advise patient to notify health care professional if they smoke.
  • May cause dizziness. Caution patient to avoid driving and other activities requiring alertness until response to medication is known.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Caution female patients that riociguat may harm fetus. Instruct females to use effective contraception (intrauterine device IUD, contraceptive implants, tubal sterilization) or a combination of methods (hormone method with a barrier method or two barrier methods) during and for at least a mo following discontinuation of therapy. If a partner’s vasectomy is method of contraception, a hormone or barrier method must be used along with this method. Counsel patient on emergency contraception. May decrease sperm count in male patients. Advise female patient to notify health care professional immediately if pregnancy is suspected and avoid breastfeeding.

Evaluation/Desired Outcomes

  • Increased exercise tolerance.
References in periodicals archive ?
The recently launched products the anticoagulant Xarelto , the eye medicine Eylea , the cancer drugs Stivarga and Xofigo , and Adempas to treat pulmonary hypertension continued to experience encouraging growth, posting combined sales of EUR 1,082 million (Q3 2014: EUR 750 million).
22, 2015 /PRNewswire/ -- Bayer HealthCare will present several abstracts related to Adempas (riociguat) at a scientific forum investigating different treatment plans and outcomes associated with pulmonary arterial hypertension (PAH) at CHEST 2015, the annual meeting of the American College of Chest Physicians, to be held October 24-28 in Montreal, Canada.
Newly launched drugs Xarelto, Eylea, Stivarga, Xofig and Adempas, posted combined sales of 2.
Following the approval of Adempas in January 2014 for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgery, Adempas is now the first drug approved in Japan to treat two forms of pulmonary hypertension (PH).
New drug launches also contributed to the overall success of Bayer's Healthcare subgroup, specifically the anticoagulant Xarelto for stroke and thrombosis prophylaxis; Eylea for age-related macular degeneration and macular edema; Stivarga for advanced metastatic colorectal cancer; Xofigo for bone metastases in prostate cancer; and Adempas for pulmonary hypertension.
At the same time, Merck has also inked clinical development collaboration deal with Bayer to market and develop its portfolio of soluble guanylate cyclase (sGC) modulators including Adempas (riociguat) and vericiguat.
At the American Thoracic Society meeting, we will share Bayer's recent, extensive research in the field of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, including new data from ongoing study of Adempas (riociguat)," said Dario Mirski, MD, Vice President and Head, U.
Data presented at the European Respiratory Society (ERS) Congress today confirm the safety profile and the sustained efficacy of Adempas (riociguat) over at least two years of treatment in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment, and in patients with pulmonary arterial hypertension (PAH).
The addition of newly approved pharmaceutical products like Xarelto, Eylea, Xofigo, Adempas and Stivarga has given a boost to the HealthCare segment at Bayer.
This excellent performance was driven by the recently launched medicines Xarelto, Eylea, Stivarga, Xofigo and Adempas, which registered combined sales of EUR 598 million (Q1 2013: EUR 244 million) led by the anticoagulant Xarelto, which is Bayer's best-selling pharmaceutical product.
Bayer today announced that Adempas (riociguat) has been approved by the European Commission for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).